Literature DB >> 10903299

The glitazones: proceed with caution.

D Krische1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10903299      PMCID: PMC1070979          DOI: 10.1136/ewjm.173.1.54

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


× No keyword cloud information.
  32 in total

1.  Pulmonary edema associated with troglitazone therapy.

Authors:  I B Hirsch; J Kelly; S Cooper
Journal:  Arch Intern Med       Date:  1999 Aug 9-23

2.  Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes.

Authors:  T Kawai; I Takei; Y Oguma; N Ohashi; M Tokui; S Oguchi; F Katsukawa; H Hirose; A Shimada; K Watanabe; T Saruta
Journal:  Metabolism       Date:  1999-09       Impact factor: 8.694

3.  Severe hepatotoxicity associated with troglitazone.

Authors:  S K Herrine; C Choudhary
Journal:  Ann Intern Med       Date:  1999-01-19       Impact factor: 25.391

Review 4.  Pharmacologic therapy for type 2 diabetes mellitus.

Authors:  R A DeFronzo
Journal:  Ann Intern Med       Date:  1999-08-17       Impact factor: 25.391

5.  Hepatic failure in a patient taking rosiglitazone.

Authors:  L M Forman; D A Simmons; R H Diamond
Journal:  Ann Intern Med       Date:  2000-01-18       Impact factor: 25.391

6.  A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients.

Authors:  J G Yu; Y T Kruszynska; M I Mulford; J M Olefsky
Journal:  Diabetes       Date:  1999-12       Impact factor: 9.461

Review 7.  Thiazolidinediones--the new insulin enhancers.

Authors:  R J Jha
Journal:  Clin Exp Hypertens       Date:  1999 Jan-Feb       Impact factor: 1.749

Review 8.  The emerging role of thiazolidinediones in the treatment of diabetes-mellitus and related disorders.

Authors:  S Subramaniam
Journal:  Clin Exp Hypertens       Date:  1999 Jan-Feb       Impact factor: 1.749

9.  Two polymorphisms in the peroxisome proliferator-activated receptor-gamma gene are associated with severe overweight among obese women.

Authors:  R Valve; K Sivenius; R Miettinen; J Pihlajamäki; A Rissanen; S S Deeb; J Auwerx; M Uusitupa; M Laakso
Journal:  J Clin Endocrinol Metab       Date:  1999-10       Impact factor: 5.958

10.  Effect of troglitazone on body fat distribution in type 2 diabetic patients.

Authors:  Y Mori; Y Murakawa; K Okada; H Horikoshi; J Yokoyama; N Tajima; Y Ikeda
Journal:  Diabetes Care       Date:  1999-06       Impact factor: 19.112

View more
  3 in total

1.  Inflammatory responses in the atria: should they stay or should they go?

Authors:  Heather S Duffy
Journal:  Heart Rhythm       Date:  2010-11-05       Impact factor: 6.343

Review 2.  Hepatotoxicity with thiazolidinediones: is it a class effect?

Authors:  A J Scheen
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 3.  Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes.

Authors:  James Xu; Rohan Rajaratnam
Journal:  Cardiovasc Diabetol       Date:  2017-02-02       Impact factor: 9.951

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.